CF
KLRS

CNA Financial’s Kalaris Therapeutics KLRS Stock Holding History

CNA Financial’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-583
Closed -$265K – 203
2021
Q2 		$265K Buy
583
+74
+15% +$38.2K 0.08% 192
2021
Q1 		$274K Buy
509
+18
+4% +$15.1K 0.08% 190
2020
Q4 		$434K Buy
491
+24
+5% +$18.5K 0.14% 171
2020
Q3 		$295K Buy
+467
New +$319K 0.11% 169

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

CNA Financial's KLRS Position: Q3 2021 in Review

CNA Financial sold out of Kalaris Therapeutics (KLRS) in Q3 2021, closing a stake of 583 shares — an estimated $265K sold.

CNA Financial first reported a position in KLRS in Q3 2020 and held it in 4 quarters. The position peaked at $434K in Q4 2020. 79 funds tracked by Wall St. Rank hold KLRS as of Q3 2021.

  • CNA Financial reported no remaining Kalaris Therapeutics position as of Q3 2021 after selling out during the quarter.
  • CNA Financial sold 583 Kalaris Therapeutics shares in Q3 2021, an estimated $265K.
  • CNA Financial first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 4 quarters.
  • CNA Financial's Kalaris Therapeutics position peaked at $434K in Q4 2020.
  • 79 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2021.

Based on CNA Financial's 13F filing for Q3 2021, filed 12 Nov 2021.